We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Kensey Nash and Orthovita jointly announced they have expanded on their existing
relationship and have agreed to pursue co-development of soft tissue repair
products for orthopedics.
Biotech Living Cell Technologies (LCT) has signed a letter of intent with California-based
Theracyte and Baxter to acquire Theracyte's technology and intellectual property
rights on cell therapy.
Nephros announced it has entered into an agreement with Asahi Kasei Medical,
a business unit of Asahi Kasei, granting Asahi Kasei Medical exclusive rights
to manufacture and distribute filter products based on the Nephros OLpur MD190
hemodiafilter in Japan for 10 years.
Cbr Systems (Cord Blood Registry), a provider of services for the storing and
processing of newborn cord blood stem cells, announced that it has filed a complaint
against ViaCell and its wholly owned subsidiary Viacord for false and misleading
advertising and related unlawful conduct.
A Boston Scientific engineer in financial straits was arrested at work for allegedly
swindling $150,000 from the medical technology giant by filing false expense
reports and then doctoring receipts to hide his spending, prosecutors said.
Align Technology, the inventor of Invisalign, a proprietary method of straightening
teeth without wires and brackets, announced that the San Francisco County Superior
Court has issued an order for a Stipulated Preliminary Injunction in Align's
multiclaim lawsuit against defendants OrthoClear, OrthoClear Holdings and individual
defendants and former Align employees Muhammad Ziaullah Chishti, Bao Tran, Peter
Riepenhausen, Joe Breeland, Jeff Tunnell, Christopher Kawaja and Charles Wen.
Cyberonics has received approval from the regulatory agencies in Korea and Brazil
to market the VNS Therapy Models 102 and 102R Generators, and the VNS Therapy
Model 302 Leads in Korea and Brazil for the treatment of pharmacoresistant epilepsy.
Fujirebio Diagnostics (FDI) has signed a distributor agreement with Australian-based
Vital Diagnostics for its new blood test for mesothelioma, MESOMARK, marking
the beginning of the company's commercial roll-out of MESOMARK, which is now
available for the first time in Australia.